Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.
Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees on March 29, 2023. The awards include options to purchase a total of 30,000 shares at an exercise price of $2.03, equivalent to the stock's closing price on the grant date. The options will vest at a rate of 1/16th quarterly over ten years, contingent upon continued employment. Savara's lead program, molgramostim nebulizer solution, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Savara Inc. (Nasdaq: SVRA) announced that its pivotal Phase 3 IMPALA-2 trial evaluating molgramostim for autoimmune Pulmonary Alveolar Proteinosis is on track, with top-line data expected by the end of Q2 2024. Following a positive review from the Independent Data Monitoring Committee, the trial proceeds unmodified. The company also reported a net loss of $10.3 million for Q4 2022, maintaining a stable loss per share of $(0.07), and ended 2022 with $125.9 million in cash. Savara aims to launch a global aPAP market development campaign in 2H23 and believes it is sufficiently capitalized through 2025.
Savara Inc. (NASDAQ: SVRA) announced its management team's participation at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 1:20pm ET. A live webcast of the presentation will be available on Savara's website and archived for 90 days.
The company focuses on rare respiratory diseases and is in Phase 3 development of its lead program, molgramostim nebulizer solution, targeting autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via the investigational eFlow® Nebulizer System, developed in collaboration with PARI Pharma GmbH.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced the granting of inducement awards to Robert M. Lutz, its new Chief Operating Officer, who joined on February 13, 2023. The award includes options to purchase 350,000 shares and RSUs for 140,000 shares, under the Savara 2021 Inducement Equity Incentive Plan. The options have an exercise price of $2.53 per share, equal to the closing price on the grant date, and vest quarterly over ten years. The RSUs fully vest after two years of employment. Savara focuses on rare respiratory diseases, with its lead program in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced key appointments to its leadership team, including Rob Lutz as Chief Operating Officer, Scott Wilhoit as Executive Vice President, Global Commercial, and Dave Lowrance as Chief Financial and Administrative Officer. The company is focused on completing enrollment for the IMPALA-2 Phase 3 trial of molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis (aPAP), aiming to deliver top-line results by the end of Q2 2024. These changes underscore Savara's commitment to advancing its rare respiratory disease therapies.